Evidence map›Paper›PMID 38873357›Full record

ArticleBJUI compass2024

CEA (CEACAM5) expression is common in muscle-invasive urothelial carcinoma of the bladder but unrelated to the disease course.

Henning Plage, Kira Furlano, Jörg Neymeyer, Sarah Weinberger, Benedikt Gerdes, Mandy Hubatsch, Bernhard Ralla, Antonia Franz, Annika Fendler, Michela de Martino and 24 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJUI compass, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Erratum.BJUI compass · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors.

Henning PlageDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Kira FurlanoDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Jörg NeymeyerDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Sarah WeinbergerDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Benedikt GerdesDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Mandy HubatschDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Bernhard RallaDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Antonia FranzDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Annika FendlerDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Michela de MartinoDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Florian RoßnerInstitute of Pathology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Simon SchallenbergInstitute of Pathology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Sefer ElezkurtajInstitute of Pathology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Martina KluthInstitute of Pathology University Medical Center Hamburg-Eppendorf Hamburg Germany.
Maximilian LennartzInstitute of Pathology University Medical Center Hamburg-Eppendorf Hamburg Germany.
Niclas C BlessinInstitute of Pathology University Medical Center Hamburg-Eppendorf Hamburg Germany.
Andreas H MarxDepartment of Pathology Academic Hospital Fuerth Fuerth Germany.
Henrik SamtlebenDepartment of Pathology Academic Hospital Fuerth Fuerth Germany.
Margit FischDepartment of Urology University Medical Center Hamburg-Eppendorf Hamburg Germany.
Michael RinkDepartment of Urology Marienhospital Hamburg Hamburg Germany.
Krystian KaczmarekDepartment of Urology and Urological Oncology Pomeranian Medical University Szczecin Poland.
Thorsten EckeDepartment of Urology Helios Hospital Bad Saarow Bad Saarow Germany.
Steffen HallmannDepartment of Urology Helios Hospital Bad Saarow Bad Saarow Germany.
Stefan KochDepartment of Pathology Helios Hospital Bad Saarow Bad Saarow Germany.
Nico AdaminiDepartment of Urology Albertinen Hospital Hamburg Germany.
Sarah MinnerInstitute of Pathology University Medical Center Hamburg-Eppendorf Hamburg Germany.
Ronald SimonInstitute of Pathology University Medical Center Hamburg-Eppendorf Hamburg Germany.ORCID https://orcid.org/0000-0003-0158-4258
Guido SauterInstitute of Pathology University Medical Center Hamburg-Eppendorf Hamburg Germany.
Joachim WeischenfeldtDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Tobias KlatteDepartment of Urology Helios Hospital Bad Saarow Bad Saarow Germany.
Thorsten SchlommDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
David HorstInstitute of Pathology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Henrik ZechaDepartment of Urology Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health Berlin Germany.
Marcin SlojewskiDepartment of Urology and Urological Oncology Pomeranian Medical University Szczecin Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Carcinoembryonic antigen (CEA) is a cell surface glycoprotein that represents a promising therapeutic target. Serum measurement of shedded CEA can be utilized for monitoring of cancer patients. Material and Methods: To evaluate the potential clinical significance of CEA expression in urothelial bladder neoplasms, CEA was analysed by immunohistochemistry in more than 2500 urothelial bladder carcinomas in a tissue microarray format. Results: CEA staining was largely absent in normal urothelial cells but was observed in 30.4% of urothelial bladder carcinomas including 406 (16.7%) with weak, 140 (5.8%) with moderate, and 192 (7.9%) with strong staining. CEA positivity occurred in 10.9% of 411 pTaG2 low-grade, 32.0% of 178 pTaG2 high-grade, and 43.0% of 93 pTaG3 tumours ( Conclusion: CEA increases markedly with grade progression in pTa tumours, and expression occurs in a significant fraction of pT2-4 urothelial bladder carcinomas. The high rate of CEA positivity in pT2-4 carcinomas offers the opportunity of using CEA serum measurement for monitoring the clinical course of these cancers. Moreover, CEA positive urothelial carcinomas are candidates for a treatment by targeted anti-CEA drugs.

Indexed as

bladder cancerCEACEACAM5immunohistochemistryprognosistissue microarray

Identifiers

PMID38873357
PMCPMC11168773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.